• Publications
  • Influence
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewedExpand
  • 1,457
  • 112
  • PDF
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes andExpand
  • 2,221
  • 88
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor ofExpand
  • 1,995
  • 63
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluatingExpand
  • 1,115
  • 61
  • PDF
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
PURPOSE To update the 2000 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSF). UPDATE METHODOLOGY The Update Committee completed a reviewExpand
  • 1,504
  • 59
  • PDF
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
PURPOSE Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previouslyExpand
  • 1,561
  • 56
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from
We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulativeExpand
  • 1,484
  • 47
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
BACKGROUND About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, suchExpand
  • 1,311
  • 39
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
BACKGROUND Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial treatment with chlorambucil. We compared the efficacy of fludarabine with that ofExpand
  • 1,037
  • 38
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, theExpand
  • 1,163
  • 26
...
1
2
3
4
5
...